Price of New A.L.S. Treatment Will Be $158,000 Per Year, Maker Says

Health
By BY PAM BELLUCK from NYT Health https://ift.tt/RSbdqvE
via IFTTT Clinical Trials, Drugs (Pharmaceuticals), Amyotrophic Lateral Sclerosis The list price of the therapy, Relyvrio, is much higher than an economic research group recommends, but the company says most patients will pay very little themselves.

Comments

Post a Comment

Popular posts from this blog

F.D.A. Poised to Restrict Access to Covid Vaccines

Image
Health By Christina Jewett and Apoorva Mandavilli from NYT Health https://ift.tt/VHvAQN8 via IFTTT Vaccination and Immunization, Coronavirus (2019-nCoV), Regulation and Deregulation of Industry, Rumors and Misinformation, Clinical Trials, Medicine and Health Agency leaders said there was evidence to justify approval only for older people and those with medical conditions. Many others may not be able to get the shots.
Read more

U.S. Will No Longer Recommend Covid Shots for Children and Pregnant Women

Image
Health By Apoorva Mandavilli and Christina Jewett from NYT Health https://ift.tt/lefLSPp via IFTTT Vaccination and Immunization, Children and Childhood, United States Politics and Government, Regulation and Deregulation of Industry, Babies and Infants, Pregnancy and Childbirth, Coronavirus (2019-nCoV) Health Secretary Robert F. Kennedy Jr. announced that the vaccine would not be included as part of the immunization schedule for healthy children.
Read more